We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


RNAi Technology Offers New Hope for Controlling Cholesterol

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "RNAi Technology Offers New Hope for Controlling Cholesterol"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Statin pills are the gold standard for treating high cholesterol, but research published in the New England Journal of Medicine this month is generating excitement about a new class of cholesterol-lowering therapies based on RNAi technology.

In an accompanying editorial, Anastasia Khvorova, PhD, professor of molecular medicine and biochemistry & molecular pharmacology, explains the promise of oligonucleotide therapeutics, including the results of a Phase I clinical trial of a new injectable drug.

“This is noteworthy as the result describes an unprecedented duration of effect for the RNAi drug, and that’s why we are so enthusiastic about the data,” said Dr. Khvorova, who was not involved in the study.

The drug, inclisiran, was developed by Alnylam Pharmaceuticals, a company co-founded by Phillip Zamore, PhD, Howard Hughes Medical Institute Investigator, the Gretchen Stone Cook Chair of Biomedical Sciences and professor of biochemistry & molecular pharmacology.

Researchers tested inclisiran and found it cut low-density lipoprotein LDL, or bad cholesterol, by half or more. The drug prompts the liver to flush more LDL cholesterol out of the bloodstream by blocking a protein called PCSK9. According to the early data, inclisiran significantly reduced levels of PCSK9 and LDL cholesterol for six months following one single injection.

“The first generation of PCSK9 inhibitors required patients to received up to 24 injection year, which is expensive and inconvenient for the patient,” said Khvorova.

Researchers estimate patients would only need an injection of Inclisiran two to three times a year to control their cholesterol.

While the results are early, Khvorova said, “We are on the right path to changing the future of how we treat bad cholesterol.”

This article has been republished from materials provided by University of Massachusetts Medical School. Note: material may have been edited for length and content. For further information, please contact the cited source.